The Negatives of Mounjaro: What the Evidence Actually Shows

You've heard the weight-loss numbers. Here's what the same trials recorded on the other side of the ledger.

Most people researching Mounjaro find the headline figures fast: around 20–21% average body-weight reduction at the highest dose in the SURMOUNT-1 trial, published in the New England Journal of Medicine. What the same data shows, less prominently, is that roughly 80% of participants on tirzepatide experienced at least one gastrointestinal side effect. Nausea leads the list. Vomiting, diarrhoea, constipation, reflux and burping follow. Fatigue and headache are also common, particularly in the first weeks of each new dose level.

These effects are real and, for some people, genuinely disruptive. The design of the titration schedule (starting at 2.5 mg and stepping up roughly every four weeks) exists partly to give your digestive system time to adjust rather than hitting it with a therapeutic dose from day one. That's worth understanding before you start, not after. The full profile of Mounjaro's negative effects and how to manage them is covered separately, but the short version is that most GI symptoms ease within days to a couple of weeks at each dose level, and they do settle for most people over time.

Injection-site reactions (redness, itching, a small lump) are also reported, though serious skin responses are less common. If you notice spreading hives or an unusual skin reaction, that warrants prompt attention; you can read more about Mounjaro and hives specifically.

The risks that come with formal regulatory warnings

Two risks sit a level above the common side effects because regulators have issued specific guidance on them.

First: acute pancreatitis. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines (including tirzepatide) flagging acute pancreatitis as an infrequent but serious risk. The symptom to act on immediately is severe, persistent stomach pain that radiates to the back, with or without vomiting. Stop the medicine and seek urgent medical attention. This isn't a reason most people shouldn't use Mounjaro, but it is a reason everyone should know the symptom before they start.

Second: absorption of oral contraceptives. Mounjaro slows gastric emptying, which can reduce how much of an oral contraceptive pill is absorbed. Women taking the pill are advised to use an additional non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase. NHS guidance notes this interaction specifically for tirzepatide; the equivalent concern hasn't been demonstrated with the same clarity for semaglutide. If you take oral HRT, NHS England also advises discussing a switch to transdermal HRT with your doctor.

Mounjaro carries a Black Triangle (▼) designation from the MHRA, meaning it is subject to additional monitoring as a relatively new medicine. That doesn't mean it is unsafe, it means post-market data continues to be collected and reviewed.

The practical downsides: cost, commitment and what can't be rushed

Cost is a meaningful negative for many people. Eli Lilly raised Mounjaro's UK list price significantly from September 2025, the highest-dose pen's list price moved from around £122 to around £330. Private providers typically charge somewhere in the £149–£375 per month range depending on dose and service. How Mounjaro pricing works in the UK is worth reading before you commit, because what a headline price includes varies considerably between providers.

There is also the matter of time. The titration schedule typically runs four to six months before a patient reaches a maintenance dose. Some people find the earlier doses feel like they're waiting for the medicine to actually work. Results during the starter period are usually modest; the stronger effects accumulate at higher doses.

A quick word on a misconception worth setting down gently: some people assume the side effects and slowness mean Mounjaro isn't working. In clinical practice, the dose increases are the mechanism, not a sign of treatment failure. The starter period is doing something, it's just not the headline-grabbing something yet.

Mounjaro is also not suitable for everyone. People with a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, or certain gastrointestinal conditions need to discuss those histories with a prescriber before starting. Pregnancy, breastfeeding, trying to conceive, and being under 18 are clear contraindications. If you are weighing Mounjaro against other options, the alternatives licensed for weight loss in the UK may be worth exploring as part of the same conversation.

Interactions, laxatives and other practical questions

Because Mounjaro slows the movement of food through the gut, it can alter how (and how quickly) other medicines are absorbed. This is relevant if you take regular oral medicines, including some sedatives and anxiolytics. If you want to understand how diazepam interacts with Mounjaro, the short answer is that it warrants a conversation with your prescriber, not an assumption that it's fine.

Constipation is one of the more persistent side effects for some patients. People naturally wonder about over-the-counter remedies. Whether laxatives are appropriate on Mounjaro depends on the type and your clinical picture, it's a question our prescribers field regularly, and the answer isn't a simple yes or no for all laxatives.

The NHS covers the full patient-level overview (side effects, storage, and what to tell your doctor) on its tirzepatide information page. Any suspected side effect can also be reported directly through the Yellow Card scheme at yellowcard.mhra.gov.uk, which helps regulators build the ongoing picture for newer medicines like Mounjaro.

If you're weighing all of this up and want a clinical view of whether Mounjaro suits your situation, a prescriber at nume can work through it with you. Speak to our prescribers, the consultation is free and reviewed the same day by a real clinician, not software.